Showing results (41-50 of 451) with videos related to

Sort By:
Pageof 46
Journal of Lipid Research|January 31, 2018
The role of lipoprotein (a) in chronic kidney diseaseJemma C Hopewell, Richard Haynes, Colin Baigent
Kidney International|November 18, 2017
Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammationBenjamin C Storey, Natalie Staplin, Richard Haynes, et al.
Hypertension (Dallas, Tex. : 1979)|February 23, 2017
Adiposity and Blood Pressure in 110 000 Mexican AdultsLouisa Gnatiuc, Jesus Alegre-Díaz, Jim Halsey, et al.
Atherosclerosis|January 2, 2016
Management of residual risk after statin therapyChristina Reith, Jane Armitage
Circulation. Genomic and Precision Medicine|February 17, 2018
Impact of Apolipoprotein(a) Isoform Size on Lipoprotein(a) Lowering in the HPS2-THRIVE StudySarah Parish, Jemma C Hopewell, Michael R Hill, et al.
European Heart Journal|July 24, 2020
Independent risk factors for simvastatin-related myopathy and relevance to different types of muscle symptomJemma C Hopewell, Alison Offer, Richard Haynes, et al.
Seminars in Dialysis|November 10, 2007
Misleading associations between cholesterol and vascular outcomes in dialysis patients: the need for randomized trialsColin Baigent, Martin J Landray, David C Wheeler
Chest|July 24, 2008
Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)Carlo Patrono, Colin Baigent, Jack Hirsh, et al.
Clinical Kidney Journal|September 9, 2020
Erratum: The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY studyWilliam G Herrington, David Preiss, Richard Haynes, et al.
Clinical Kidney Journal|December 8, 2018
The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY studyWilliam G Herrington, David Preiss, Richard Haynes, et al.
Pageof 46